Foli-seq™ profiles host RNA from exfoliated gut epithelial and immune cells to reveal mucosal inflammation, barrier function, disease biology, and therapeutic response.
Starting from routine stool samples, Foli-seq™ captures stool-derived host RNA from naturally shed gut cells and converts it into longitudinal transcriptomic readouts.
Every day, the gastrointestinal tract responds to food, medicines, and environmental exposures. These responses shape local mucosal biology, but they are difficult to monitor over time. Biopsy can access tissue directly, but is invasive and episodic. Blood captures systemic signals, but can miss what is happening at the gut lining. Microbiome profiling characterizes microbial communities, but does not directly measure the human host response.
Stool is one of the few sample types that can repeatedly and non-invasively capture material shed directly from the gut. Foli-seq™ uses this biology to measure stool-derived host RNA from naturally shed epithelial and immune cells — not just microbial composition.
How Foli-seq™ worksStarting from routine stool samples, Foli-seq™ measures host RNA from naturally shed epithelial and immune cells — not just microbial composition.
These insights reveal inflammation, barrier damage, tissue repair, treatment response, and polyp- or CRC-associated changes in the gut lining.
Panels are available for human translational studies, mouse preclinical models, and companion animal programs.
View full platform Explore Foli-seq™ panelsNon-invasive host gut transcriptomics for clinical and preclinical drug development, pharmacodynamic monitoring, patient stratification, and responder prediction.
Host gut transcriptomic signatures for non-invasive disease monitoring, therapy response prediction, treatment guidance, and CRC / advanced adenoma screening.
A growing host gut transcriptomic data platform for precision medicine modeling, patient subtype discovery, and multi-omic integration.
Foli Bio is advancing host RNA signatures across gastrointestinal disease areas to support disease monitoring, risk stratification, therapy response assessment, and non-invasive molecular diagnostics.
Host transcriptomic signatures for IBD disease activity monitoring, mucosal response assessment, and anti-TNF response prediction.
Host RNA signatures associated with colorectal polyps, adenomas, and polyp-associated changes in the gut lining for non-invasive screening applications in high-risk and average-risk cohorts.
Additional host gut transcriptomic programs advancing with pharma, academic, and translational partners. Collaborator details not publicly disclosed.
We work with pharma, biotech, academic, and translational research partners. Contact us to learn more about the Foli-seq™ platform, ongoing studies, and partnership opportunities.